Guangzhou Innogen Pharmaceutical Group Co Ltd (HKSE:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
96

Recommended

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.

Malik Ahmed Khan, CFA | 05 September 2025

A difficult year but better times ahead.

Johannes Faul, CFA | 05 September 2025

Find out how this defensive player has fared after earnings.

Simonelle Mody | 03 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,140.50	11.00	0.12%
CAC 40	7,656.10	42.82	-0.56%
DAX 40	23,625.66	144.67	-0.61%
Dow JONES (US)	45,316.53	304.76	-0.67%
FTSE 100	9,204.98	11.89	-0.13%
HKSE	25,417.98	359.47	1.43%
NASDAQ	21,621.71	85.98	-0.40%
Nikkei 225	43,018.75	438.48	1.03%
NZX 50 Index	13,223.53	90.33	0.69%
S&P 500	6,464.58	37.50	-0.58%
S&P/ASX 200	8,871.20	8.60	0.10%
SSE Composite Index	3,812.51	46.64	1.24%